BITT secures NIH funding for pioneering Sjögren’s syndrome treatment
Boston Immune Technologies and Therapeutics, Inc. (BITT), a leading clinical-stage biotechnology firm specializing in tumor necrosis factor superfamily receptor (TNFSR) antagonist antibodies, has received a ... Read More